Dec 30, 2025 • ts2.tech
SOMEWHAT-BULLISH
Belite Bio stock swings to $170 and closes up nearly 7% as rally stays hot into year-end
Belite Bio's U.S.-listed shares surged nearly 7% and swung between $151.50 and $169.75, closing at $165.29, driven by investor interest in its rare-disease eye drug. This rally comes after major December announcements, including positive late-stage trial results for its Stargardt disease treatment and a $350 million equity offering. The company plans to file for U.S. approval in early 2026 for its oral drug tinlarebant, which currently has no FDA-approved alternatives for the condition.
Dec 27, 2025 • AD HOC NEWS
BULLISH
ARK Innovation ETF Charts a Potential Path to Recovery
The ARK Innovation ETF (ARKK) is showing technical signs of recovery as 2025 concludes, benefiting from moderating interest rate expectations and a market shift towards software applications. Trading at $80.65, ARKK is above its 50-day and 200-day moving averages, forming a "Golden Cross" indicative of bullish momentum. However, its concentrated portfolio, with top holdings like Tesla and Coinbase, presents elevated risk while offering potential for superior returns.
Dec 27, 2025 • ts2.tech
NEUTRAL
Regencell Bioscience (RGC) Stock Slides 14% Into the Weekend: Latest News, Risks, and What to Watch Monday
Regencell Bioscience (RGC) stock experienced a significant 14% drop on Friday, closing at $21.16, prompting investors to scrutinize its financial health and operational risks. The decline is attributed to thin liquidity and the stock's historical volatility, rather than specific corporate news. Key concerns include its "pre-revenue" status, substantial ongoing losses, a "going concern" warning from management, and a DOJ investigation into trading of its shares.
Dec 25, 2025 • MarketBeat
NEUTRAL
Harbor Capital Advisors Inc. Trims Stock Holdings in Magnite, Inc. $MGNI
Harbor Capital Advisors Inc. significantly reduced its stake in Magnite, Inc. by 72.8% in the third quarter, now holding 172,171 shares valued at approximately $3.75 million. The company has seen net selling from insiders, while institutional investors own a substantial 73.40% of the stock. Magnite (NASDAQ:MGNI) reported strong Q3 earnings with revenue surpassing estimates, and analysts currently rate the stock as a "Moderate Buy" with an average target price of $26.20.
Dec 24, 2025 • TipRanks
BULLISH
SPY ETF Daily Update, 12/24/2025
The SPDR S&P 500 ETF Trust (SPY) gained 0.35% on Wednesday, fueled by strong U.S. economic data, easing inflation, and robust technology stocks. The ETF saw $3 billion in net outflows over five days, despite positive retail sentiment, while hedge funds decreased their holdings. SPY has a "Moderate Buy" rating with an average price target implying 15.18% upside, and an ETF Smart Score of eight.
Dec 23, 2025 • The Globe and Mail
SOMEWHAT-BULLISH
Analysts Offer Insights on Technology Companies: Adobe (ADBE), Wix (WIX) and Accenture (ACN)
This article details recent analyst ratings for Adobe (ADBE), Wix (WIX), and Accenture (ACN). Wells Fargo analysts maintained Buy ratings for Adobe and Wix, and a Hold rating for Accenture, with specific price targets and analyst consensus ratings indicating potential upsides for Adobe and Wix, and a moderate buy for Accenture. The report provides insights into each company's recent stock performance and analyst sentiment.